Investigational drug · Phase 2
GSK3528869A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatitis B, Chronic.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "GSK3528869A"
First trial start
2022
Mar 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK3528869A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatitis B, Chronic
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK3528869A" as an intervention, largest first.
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B InfectionPivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT03866187 · 236 participants · Start Mar 28, 2019 · Primary completion Oct 7, 2024
Drug: ChAd155-hIi-HBV low dose formulation; ChAd155-hIi-HBV high dose formulation and 5 more · For: Hepatitis B, Chronic
Sites: Antwerp, Belgium; Brussels, Belgium; Edegem, Belgium · 43 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05276297 · 174 participants · Start Mar 22, 2022 · Primary completion Aug 5, 2025
Drug: GSK3228836; GSK3528869A and 1 more · For: Hepatitis B, Chronic
Sites: Edegem, Belgium; Sliven, Bulgaria; Sofia, Bulgaria · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hepatitis B, Chronic
- ElebsiranVIR-2218, BRII-835Phase 38 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection
- VIR-3434TobevibartPhase 35 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Hepatitis B, Chronic
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.